BR112017027951A2 - composto inibitório de brk - Google Patents

composto inibitório de brk

Info

Publication number
BR112017027951A2
BR112017027951A2 BR112017027951-7A BR112017027951A BR112017027951A2 BR 112017027951 A2 BR112017027951 A2 BR 112017027951A2 BR 112017027951 A BR112017027951 A BR 112017027951A BR 112017027951 A2 BR112017027951 A2 BR 112017027951A2
Authority
BR
Brazil
Prior art keywords
brk
compound
inhibitory compound
brk inhibitory
symbols
Prior art date
Application number
BR112017027951-7A
Other languages
English (en)
Japanese (ja)
Inventor
Yamamoto Shingo
Tokura Hiroshi
Kurono Masakuni
Nomura Yoshinori
Hotta Shingo
Original Assignee
Ono Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co., Ltd. filed Critical Ono Pharmaceutical Co., Ltd.
Publication of BR112017027951A2 publication Critical patent/BR112017027951A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a um composto representado pela fórmula geral (i) (em que, todos os símbolos representam os mesmos significados como os símbolos apresentados no relatório descritivo), um sal deste, um solvato deste, um n-óxido deste ou um pró-fármaco de qualquer um destes. visto que o composto tem uma atividade inibitória de brk, o composto é útil como um ingrediente medicamentoso para a prevenção e/ou tratamento de doenças relacionadas a brk tal como câncer, por exemplo.
BR112017027951-7A 2015-06-22 2016-06-21 composto inibitório de brk BR112017027951A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-124315 2015-06-22
JP2015124315 2015-06-22
PCT/JP2016/068429 WO2016208595A1 (ja) 2015-06-22 2016-06-21 Ｂｒｋ阻害化合物

Publications (1)

Publication Number Publication Date
BR112017027951A2 true BR112017027951A2 (pt) 2018-08-28

Family

ID=57584946

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017027951-7A BR112017027951A2 (pt) 2015-06-22 2016-06-21 composto inibitório de brk

Country Status (17)

Country Link
US (2) US10377759B2 (pt)
EP (1) EP3312182B9 (pt)
JP (1) JP6819585B2 (pt)
KR (1) KR20180015160A (pt)
CN (1) CN107709327A (pt)
AU (1) AU2016284402B2 (pt)
BR (1) BR112017027951A2 (pt)
CA (1) CA2990145A1 (pt)
ES (1) ES2909048T3 (pt)
HK (1) HK1250159A1 (pt)
IL (1) IL256414A (pt)
MX (1) MX2017016325A (pt)
PH (1) PH12017502363A1 (pt)
RU (1) RU2719477C2 (pt)
SG (1) SG11201710604SA (pt)
WO (1) WO2016208595A1 (pt)
ZA (1) ZA201708699B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019537585A (ja) 2016-10-28 2019-12-26 アイカーン スクール オブ メディスン アット マウント シナイ Ｅｚｈ２媒介性がんを治療するための組成物および方法
WO2018106870A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
ES2909234T3 (es) * 2016-12-21 2022-05-05 Ono Pharmaceutical Co Compuestos de 6-amino-7,9-dihidro-8H-purin-8-ona como inhibidores de Brk
CA3092011A1 (en) 2018-03-02 2019-09-06 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical compounds
CA3092677A1 (en) 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
US20230070613A1 (en) * 2018-07-05 2023-03-09 Icahn School Of Medicine At Mount Sinai Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use
US20220363693A1 (en) * 2018-07-24 2022-11-17 Taiho Pharmaceutical Co., Ltd. Heterobicyclic compounds for inhibiting the activity of shp2
AU2020267661A1 (en) 2019-05-08 2021-12-23 Vimalan Biosciences, Inc. JAK inhibitors
CN115038436A (zh) 2019-08-08 2022-09-09 维玛兰生物科学公司 Jak抑制剂
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
CA3188639A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
CN112830936B (zh) * 2021-01-08 2022-01-28 广西师范大学 核黄素化合物、其制备方法及应用
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
CN115466264A (zh) * 2021-06-11 2022-12-13 腾讯科技（深圳）有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007373A4 (en) 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
DK2081435T3 (en) 2006-09-22 2016-08-15 Pharmacyclics Llc INHIBITORS OF BRUTON'S TYROSINKINASE
US20100331297A1 (en) * 2007-11-07 2010-12-30 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
CA2732628A1 (en) * 2008-08-01 2010-02-04 Biocryst Pharmaceuticals, Inc. Therapeutic agents
CN105188704B (zh) * 2013-01-16 2017-09-19 西格诺药品有限公司 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法

Also Published As

Publication number Publication date
CA2990145A1 (en) 2016-12-29
WO2016208595A1 (ja) 2016-12-29
EP3312182B9 (en) 2022-06-29
US11512087B2 (en) 2022-11-29
US10377759B2 (en) 2019-08-13
JPWO2016208595A1 (ja) 2018-04-05
ZA201708699B (en) 2018-11-28
EP3312182B1 (en) 2022-02-23
AU2016284402B2 (en) 2020-04-02
ES2909048T3 (es) 2022-05-05
RU2017145026A (ru) 2019-07-23
HK1250159A1 (zh) 2018-11-30
PH12017502363A1 (en) 2018-06-25
AU2016284402A1 (en) 2018-01-18
JP6819585B2 (ja) 2021-01-27
EP3312182A4 (en) 2018-12-12
KR20180015160A (ko) 2018-02-12
US20190315756A1 (en) 2019-10-17
RU2017145026A3 (pt) 2019-12-02
RU2719477C2 (ru) 2020-04-17
IL256414A (en) 2018-02-28
EP3312182A1 (en) 2018-04-25
CN107709327A (zh) 2018-02-16
SG11201710604SA (en) 2018-01-30
MX2017016325A (es) 2018-03-02
US20180186800A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
BR112017027951A2 (pt) composto inibitório de brk
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
BR112019002576A2 (pt) composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
MX2019002356A (es) Compuestos de biarilo utiles como inmunomoduladores.
BR112016023558A2 (pt) compostos úteis como imunomoduladores
BR112018007381A2 (pt) compostos úteis como imunomoduladores
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112018005932A2 (pt) inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer
EA201990833A1 (ru) Соединение пиридина
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
BR112014025711A8 (pt) composto, medicamento, e, uso de um composto
BR112016017317A8 (pt) composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1
BR112018005936A2 (pt) inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
UY36080A (es) Compuestos inhibidores de metaloenzima como fungicidas.
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
CL2019000661A1 (es) Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica.
PH12016501988A1 (en) Antibacterial compounds
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements